26th July 2012

London 2012 Olympics: British Business Embassy launches today

The British Business Embassy launches today bringing together 4,000 business leaders, policy makers and investors for a series of global business summits to be held during the Olympics and Paralympic Games at the prestigious 19th century Lancaster House between 26 July and 9 September 2012.

The British Business Embassy, developed by UK Trade & Investment as part of the GREAT campaign, will help showcase global business partnerships along with the best of what the UK has to offer in some of our most successful industries including life sciences, fashion, architecture, technology, advanced engineering, automotive and aerospace.

Richmond Pharmacology is proud to be the only Phase I CRO to participate in the Life Sciences British Business Embassy Innovation Showcase taking place Thursday 2 August 2012, where we will present our unique service offering of Adaptive Phase I Studies.

Read more

Request a copy of the showcase presentation

23 August 2011

The TQT Challenge: Who cares who measures?

Good data is essential for a successful study. Whilst analysis is important, standardisation in the clinic is imperative.

Although many may claim they are specialists in conducting TQT studies, few have the data to back this up. Our published data shows that over the past decade, Richmond Pharmacology’s studies have consistently produced less variability of QT measurements when compared directly with our competitors. This confirms that we are the leading research unit for cardiac safety studies - either as a one stop solution or in conjunction with our preferred partner core labs.

At Richmond Pharmacology our mantra is good data in equals good data out.

Our 10th Birthday Promise

We are so confident and proud of our 100% success rate in TQT studies that should we fail to show assay sensitivity we will repeat the study at no cost to our sponsors.

To take us up on our promise, contact our Business Development team today to discuss your TQT study needs

Take a look at our published data »

4th August 2011

Richmond Pharmacology Celebrates 10 Years at the Henley Royal Regatta

Richmond Pharmacology Ltd is proud to announce that it recently celebrated its 10th anniversary in style with a quintessentially British day on the river at this year's Henley Royal Regatta.  The Henley Royal Regatta has been held annually since 1839 and remains one of Britain's most prestigious sporting events, and as such was a fitting place to hold this esteemed celebration.

The day started off with an official welcome by Richmond Pharmacology's co-founder and CEO, Dr Jorg Taubel, followed by a morning presentation by guest speaker, Dr Tony Soteriou, Deputy Director, Head of NHS Research Infrastructure and Industry R&D Relations from the Department of Health, looking at new initiatives to simplify the regulatory process for clinical research conducted in the United Kingdom. After the morning presentation guests attended the prestigious Fawley Meadows Restaurant to relax and enjoy the afternoon's festivities.

Richmond Pharmacology was co-founded in August 2001 by Richmond Pharmacology's three Executive Directors Dr Ulrike Lorch, Dr Radivoj Arezina and Dr Jörg Täubel, and first opened at the Atkinson Morely Hospital in Wimbledon.  10 years on, now based in two of the UK's largest acute NHS teaching hospitals, Richmond Pharmacology has undergone steady expansion and has since become one of Europe's leading full-service specialist early phase CROs. The first to obtain MHRA standard and supplementary accreditation for two hospital based clinical trial units coupled with its supreme expertise gained from over  250 early phase studies carried out to date, Richmond Pharmacology is proud to be celebrating 10 years of clinical excellence, still leading the way as the experts in the field of early phase clinical research!